← Who reports today · Health Care
DXCM · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Dexcom's revenue grew 13.1% to $1.31B, operating income jumped 49.7% to $318.3M, and net income rose 38.5% to $249.1M, or $0.64 per diluted share.
Net income
$249M
up 38.5% y/y
Revenue
$1,308M
up 13.1% y/y
Operating income
$318M
up 49.7% y/y
Gross profit
$830M
up 20.5% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Revenue | $1,308 · +13.1% |
| Cost of sales | $478 · +2.2% |
| Gross profit | $830 · +20.5% · 63.4% margin |
| Research and development | $153 · +3.2% |
| Selling, general and administrative | $359 · +9.4% |
| Operating income | $318 · +49.7% · 24.3% margin |
| Other income (expense), net | $0.8 · vs $28.5 |
| Income before income taxes | $318 · +31.7% |
| Income tax expense | $68.4 · +11.6% · 21.5% effective rate |
| Net income | $249 · +38.5% · $0.64/sh · 19.0% margin |
Verdict: Dexcom's revenue grew 13.1% to $1.31B, operating income jumped 49.7% to $318.3M, and net income rose 38.5% to $249.1M, or $0.64 per diluted share.
Source and notation
Source: DXCM press release, 8-K EX-99.1 of 07/30/2026 (SEC EDGAR).
Open as an image: DXCM, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “DXCM Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/dxcm/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/dxcm/q2-2026"><img src="https://whoreportstoday.com/t/dxcm/q2-2026/sankey.png" alt="DXCM Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/dxcm/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/dxcm/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/dxcm/q2-2026">DXCM Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- GAAP operating margin expanded 590 basis points to 24.3% of revenue, while U.S. revenue grew 11% and international revenue grew 19%.
- Operating income was $318M (+49.7% y/y), an operating margin of 24.3% vs 18.4% a year ago.
- Gross profit of $830M is a gross margin of 63.4% vs 59.5% a year ago.
- Income tax of $68.4M implies an effective rate of 21.5% vs 25.4% a year ago.
- Diluted EPS was $0.64 vs $0.45 a year ago (+42.2%), while net income changed +38.5%.
What distorts the picture in this report and what to watch beyond the headlines.
DXCM — a medical device company that develops and sells continuous glucose monitoring (CGM) systems, such as the Dexcom G7 and the over-the-counter Stelo biosensor, for people with diabetes and their clinicians.
It reports a single segment and earns revenue from sales of its CGM systems and their disposable sensors. · Source: annual report (Form 10-K, SEC)
More reports: ELV · Q3 2026 · EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · HSIC · Q2 2026 · HUM · Q2 2026 · IDXX · Q2 2026 · ILMN · Q3 2026 · INCY · Q2 2026 · all reports